Zydus Cadila, whose Covid vaccine ZyCoV-D for adults and children aged 12 and older received approval yesterday, said Saturday it hopes to produce one crore dose per month by October.
The company said it will produce 3-5 crore doses by December-January, adding that it will not be able to meet the government’s pledge of 5 crore doses in August.
It is in talks with some outside companies about a manufacturing alliance and technology transfer.
Vaccine costs, the company said, will take into account new technology and delivery mechanism.
The three-dose vaccine, developed in collaboration with the Ministry of Biotechnology, is the second homegrown injection to receive emergency approval in India after Bharat Biotech’s Covaxin. Overall, it is the sixth vaccine to be approved for use in the country.
In July, the drugmaker said its vaccine is effective against the novel coronavirus mutants, particularly the highly transmissible Delta variant. The shot is administered with a needle-free applicator as opposed to traditional syringes, it said.
Listed as Cadila Healthcare Ltd, it applied for authorization of ZyCoV-D on July 1, based on a 66.6 percent efficacy rate in a late-stage study involving more than 28,000 volunteers nationwide.
ZyCoV-D is the world’s first plasmid DNA vaccine against the coronavirus